Wall Street Zen Upgrades Inventiva (NASDAQ:IVA) to “Hold”

Inventiva (NASDAQ:IVA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Truist Financial boosted their price target on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Cantor Fitzgerald initiated coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company. Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Finally, Guggenheim lifted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Inventiva currently has a consensus rating of “Buy” and a consensus price target of $15.86.

Inventiva Stock Performance

IVA opened at $3.56 on Friday. The company’s 50-day moving average price is $4.33 and its 200 day moving average price is $4.65. Inventiva has a fifty-two week low of $3.11 and a fifty-two week high of $7.98.

Inventiva (NASDAQ:IVA) last issued its earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million during the quarter. Equities analysts expect that Inventiva will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP raised its position in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after acquiring an additional 43,280 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Inventiva during the 1st quarter valued at about $1,111,000. Persistent Asset Partners Ltd bought a new position in shares of Inventiva during the 4th quarter valued at about $603,000. NEXTBio Capital Management LP acquired a new position in shares of Inventiva in the 4th quarter worth approximately $6,039,000. Finally, Eventide Asset Management LLC acquired a new position in shares of Inventiva in the 4th quarter worth approximately $1,155,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.